Publications & Presentations

Jul 07, 2024

Potent, Specific, and Durable Liver Editing of PCSK9 in Preclinical Studies of the CRISPR Base Editing Medicine VERVE-101

VERVE-101

2024

PCSK9

May 28, 2024

An investigational in vivo base editing medicine targeting ANGPTL3, VERVE-201, achieves precise, and durable liver editing in nonclinical studies

EAS

VERVE-201

2024

ANGPTL3

May 17, 2024

Proof-of-concept for in vivo Base Editing to Inactivate the PCSK9 Gene and Lower LDL-Cholesterol in Humans

TIDES

VERVE-101, VERVE-102, VERVE-201

2024

ANGPTL3, LPA, PCSK9

May 11, 2024

Characterization of Guide RNA Site Consistency Across Ancestries and the Potential for Off-Target Editing with the Clinical-Stage Base Editing Medicine, VERVE-101

ASGCT

VERVE-101

2024

PCSK9

Nov 13, 2023

Interim Results from the heart-1 Trial of VERVE-101 & Verve Corporate Updates

AHA

VERVE-101, VERVE-102, VERVE-201

2023

ANGPTL3, PCSK9

Nov 12, 2023

Interim Results from the heart-1 Trial of VERVE-101

AHA

VERVE-101

2023

PCSK9

Aug 28, 2023

An investigational in vivo base editing medicine targeting ANGPTL3, VERVE-201, achieves potent and LDLR-independent liver editing in mouse models

ESC

VERVE-201

2023

ANGPTL3

May 26, 2023

Developing ‘once-and-done’ gene editing medicines to treat cardiovascular disease

EAS

VERVE-101, VERVE-201, GalNAc-LNP

2023

ANGPTL3, PCSK9

May 08, 2023

TIDES 2023 Keynote Address

TIDES

VERVE-101, VERVE-201

2023

ANGPTL3, PCSK9